PALLAS试验5年随访:哌柏西利联合辅助内分泌治疗早期乳腺癌
PALLAS是一项国际开放标签随机III期试验,评估在辅助内分泌治疗基础上加用2年哌柏西利对II-III期HR阳性/HER2阴性早期乳腺癌的疗效。中位随访59.8个月,5年iDFS在哌柏西利联合组为84.2%,单用内分泌治疗组为82.4%(HR 0.88,95%CI 0.77-1.01,P=0.0614),无显著获益;5年OS两组分别为92.6%和93.2%(HR 1.09,95%CI 0.89-1.33,P=0.4051)。
要点
- 加用2年哌柏西利未显著改善5年iDFS(HR 0.88,P=0.0614)。
- 5年OS两组无显著差异(HR 1.09,P=0.4051)。
- 各亚组均未观察到哌柏西利的iDFS获益。
核心结论
- 5年随访确认,在辅助内分泌治疗基础上加用2年哌柏西利未显著改善高危早期HR阳性/HER2阴性乳腺癌患者的iDFS或OS。
研究设计与样本
- PALLAS为国际、开放标签、随机III期试验,评估在辅助内分泌治疗基础上加用2年哌柏西利。
- 共入组5753例II-III期HR阳性/HER2阴性早期乳腺癌患者,2883例随机至哌柏西利联合内分泌治疗组,2870例至单用内分泌治疗组。
- 主要终点为iDFS。
主要发现
- 中位随访59.8个月,5年iDFS在哌柏西利联合组为84.2%(95%CI 82.7%-85.6%),单用内分泌治疗组为82.4%(95%CI 80.8%-83.9%),HR 0.88(95%CI 0.77-1.01),log-rank P=0.0614。
- 按解剖分期、T分期、N分期、肿瘤分级、既往(新)辅助化疗、年龄或临床风险分析的各亚组均未观察到哌柏西利的显著iDFS获益。
- 5年OS在哌柏西利联合组为92.6%(95%CI 91.5%-93.6%),单用内分泌治疗组为93.2%(95%CI 92.1%-94.1%),HR 1.09(95%CI 0.89-1.33),log-rank P=0.4051。
- 复发后接受CDK4/6抑制剂治疗的患者比例在单用内分泌治疗组为65.7%,哌柏西利联合组为33.0%;复发后接受化疗的患者比例在哌柏西利联合组为52.5%,单用内分泌治疗组为41.0%。
临床怎么用
- 不推荐在辅助内分泌治疗中常规加用2年哌柏西利用于II-III期HR阳性/HER2阴性早期乳腺癌。
- 该5年随访数据可作为当代管理HR阳性/HER2阴性乳腺癌的临床结局基准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III PALLAS trial, the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) did not improve short-term invasive disease-free survival (iDFS) compared with ET alone in high-risk early-stage hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In this article, we report 5-year efficacy outcomes, including updated iDFS and overall survival (OS). PATIENTS AND METHODS: PALLAS is an international, open-label, randomized phase III trial evaluating the addition of 2 years of palbociclib to adjuvant ET in patients with stage II-III HR-positive/HER2-negative breast cancer. The primary endpoint was iDFS. RESULTS: The trial enrolled 5753 patients, with 2883 randomized to receive palbociclib plus ET and 2870 to receive ET alone. With a median follow-up of 59.8 months, the 5-year iDFS was 84.2% [95% confidence interval (CI) 82.7% to 85.6%] in the palbociclib plus ET arm and 82.4% (95% CI 80.8% to 83.9%) in the ET-alone arm [hazard ratio (HR) 0.88, 95% CI 0.77-1.01, log-rank P = 0.0614]. No significant iDFS benefit of palbociclib was observed in any subgroup, including analyses by anatomic stage, T-stage, N-stage, tumor grade, prior (neo)adjuvant chemotherapy, age, or clinical risk. The 5-year OS was 92.6% (95% CI 91.5% to 93.6%) in the palbociclib plus ET arm and 93.2% (95% CI 92.1% to 94.1%) in the ET-alone arm (HR 1.09, 95% CI 0.89-1.33, log-rank P = 0.4051). More patients in the ET-alone arm (65.7%) than in the palbociclib plus ET arm (33.0%) received cyclin-dependent kinase 4/6 inhibitors after recurrence. Conversely, more patients in the palbociclib plus ET arm (52.5%) than in the ET-alone arm (41.0%) received chemotherapy after recurrence. CONCLUSIONS: In conclusion, 5-year follow-up from the PALLAS trial confirms initially reported results. These long-term findings will provide investigators with important benchmarks for clinical outcomes in the contemporary management of HR-positive/HER2-negative breast cancer, and may be further used to guide adjuvant therapy for patients with high-risk early-stage HR-positive/HER2-negative breast cancer.
引用
- Mayer EL, Hlauschek D, Gnant M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13). Ann Oncol. 2025. PMID: 41110701. doi:10.1016/j.annonc.2025.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。